tiprankstipranks
Advertisement
Advertisement

CTOR Stock Latest News

Citius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
Company AnnouncementsCitius Oncology Reports Positive Phase 1 LYMPHIR Combination Data
17d ago
8K
CTOR
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
PremiumThe Fly
Citius Oncology’s Lymphir shows positive results in gynecologic cancers
17d ago
CTOR
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
PremiumCompany Announcements
Citius Oncology Announces Positive Phase 1 LYMPHIR Data
23d ago
8K
CTOR
Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR
PremiumThe Fly
Citius Oncology reports results from Phase 1 trial evaluating LYMPHIR
23d ago
CTOR
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
PremiumThe Fly
Citius Oncology reports Q1 EPS (6c) vs. (9c) last year
1M ago
CTOR
CTXR
Citius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
PremiumThe FlyCitius Pharmaceuticals reports $3.9M in revenue following launch of Lymphir
1M ago
CTOR
CTXR
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
Premium
The Fly
Citius Pharmaceuticals reports Q1 EPS (41c) vs. ($1.30) last year
1M ago
CTOR
CTXR
CTOR Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
CTOR Earnings this Week: How Will it Perform?
1M ago
CTOR
Citius files to sell shares of common stock underlying warrants for holders
PremiumThe Fly
Citius files to sell shares of common stock underlying warrants for holders
3M ago
CTOR
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption
PremiumCompany Announcements
Citius Oncology’s LYMPHIR FDA Win Clouded by High Upfront Costs, Regulatory Risks, and Uncertain Market Adoption
3M ago
CTOR
Citius Oncology reports FY25 EPS (34c) vs. (31c) last year
PremiumThe Fly
Citius Oncology reports FY25 EPS (34c) vs. (31c) last year
3M ago
CTOR
Citius Oncology Raises $18M Through Direct Offering
PremiumCompany Announcements
Citius Oncology Raises $18M Through Direct Offering
4M ago
8K
CTOR
Citius Oncology to sell 1.28M shares at $1.09 in registered direct offering
PremiumThe FlyCitius Oncology to sell 1.28M shares at $1.09 in registered direct offering
4M ago
CTOR
CTXR
Citius Oncology expands Lymphir distribution to Turkey and Middle East
Premium
The Fly
Citius Oncology expands Lymphir distribution to Turkey and Middle East
4M ago
CTOR
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma
Premium
Company Announcements
Citius Oncology Launches LYMPHIR for Cutaneous T-Cell Lymphoma
4M ago
8K
CTOR
Citius Oncology announces U.S. commercial launch of LYMPHIR
PremiumThe Fly
Citius Oncology announces U.S. commercial launch of LYMPHIR
4M ago
CTOR
Citius Oncology to advance launch of Lymphir with Verix AI integration
PremiumThe Fly
Citius Oncology to advance launch of Lymphir with Verix AI integration
4M ago
CTOR
CTXR
Citius Oncology Stockholders Approve Share Increase
PremiumCompany Announcements
Citius Oncology Stockholders Approve Share Increase
5M ago
8K
CTOR
Citius Oncology Prepares LYMPHIR Launch for Q4 2025
PremiumCompany Announcements
Citius Oncology Prepares LYMPHIR Launch for Q4 2025
5M ago
8K
CTOR
Citius Oncology announces distribution agreement with McKesson
PremiumThe FlyCitius Oncology announces distribution agreement with McKesson
5M ago
MCK
CTOR
Strategic Positioning and Market Potential Drive Buy Rating for Citius Oncology’s Lymphir
Premium
Ratings
Strategic Positioning and Market Potential Drive Buy Rating for Citius Oncology’s Lymphir
5M ago
CTOR
Citius Oncology signs exclusive commercialization agreement with EVERSANA
Premium
The Fly
Citius Oncology signs exclusive commercialization agreement with EVERSANA
5M ago
CTOR
CTXR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >